ADAR1 Capital Management LLC acquired a new position in Opus Genetics, Inc. (NASDAQ: IRD) during the

RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a

RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers

Common StockPreferred StockDebt SecuritiesWarrantsUnitsand up to 34,449,749 Shares of Common Stock I

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consens

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.14) per share which beat the analyst con

Topline six-month efficacy data expected by end of 2027Phase 3 study follows FDA alignment on regist

Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on regis

Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre

Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"),

RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (t

Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elemen

Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates

Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stag

RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (t

Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and rai

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for In

Rapidly Advancing Five IRD Programs​ with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK

Citizens analyst Jonathan Wolleben reiterates Opus Genetics (NASDAQ:IRD) with a Market Outperform

https://www.sec.gov/Archives/edgar/data/1228627/000114036126024283/ny20075388x1_s3.htm

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ:IRD) with a B

RESEARCH TRIANGLE PARK, N. C. , June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD)

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“O

Opus Genetics NASDAQ: IRD is advancing a portfolio of gene therapies for inherited retinal diseases,

Leerink Partners analyst Lili Nsongo initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outp

Citizens analyst Jonathan Wolleben maintains Opus Genetics (NASDAQ:IRD) with a Market Outperform

RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“O

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.75 per share versus the Zacks Consens

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst c

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcomin

Oral PresentationRestoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5Th

Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients,

Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms

Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stag

Citizens analyst Jonathan Wolleben initiates coverage on Opus Genetics (NASDAQ:IRD) with a Market

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades and downg

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Opus Genetics (NASDAQ:IRD) with a

Oppenheimer analyst Andreas Argyrides initiates coverage on Opus Genetics (NASDAQ:IRD) with a Out

Chardan Capital analyst Daniil Gataulin maintains Opus Genetics (NASDAQ:IRD) with a Buy and raise

Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the p

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.21) per share which missed the analyst c

BTIG analyst Thomas Shrader maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price

Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stag

Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stag